

REMARKS


The amendments made herein serve to place the application in better form for prosecution by including the priority information of the application as well as correcting typographical errors.

Support for the amendments to the specification can be found in the text of the instant application. Table 2 has been amended to correct an obvious error in the ED₅₀ (mM) of lidocaine alone. Support for this correction can be found on page 20, in Table 1, where the ED₅₀ (mM) of lidocaine alone is stated to be 2.5 mM. The value for the ED₅₀ (mM) of lidocaine alone is also depicted in Figure 3b (X-axis) as 2.5mM. No new matter is added.

Support for amending the specification to state that the fixed ratio of lidocaine/buprenorphine is 2.5 mM can be found in Table 1, wherein the correct ratio of 2.4 is evident from the ED₅₀ values listed for lidocaine and buprenorphine (i.e., $0.44/0.18=2.4$). No new matter is added.

An early and favorable examination on the merits is respectfully requested.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: 
Amy Leahy
Reg. No. 47,739
(212) 588-0800